2023-000086-14 Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial
Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial
date_time
2023-07-13 15:22:00
Codice EUDRACT
2023-000086-14
Promotore
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)